Download presentation
Presentation is loading. Please wait.
Published byPhilip Dylan Pierce Modified over 6 years ago
1
Successful Coronary Artery Bypass in Types 2M and 2N von Willebrand Disease
Mathieu Fiore, MD, PhD, Marie Tuffigo, MD, Véronique Cahoreau, MD, Pierre Oses, MD, Christine Mouton, MD The Annals of Thoracic Surgery Volume 102, Issue 5, Pages e423-e425 (November 2016) DOI: /j.athoracsur Copyright © 2016 The Society of Thoracic Surgeons Terms and Conditions
2
Fig 1 Peri- and postoperative therapy in case 1. Patient was administered 1 dose of 60 IU/kg−1 of purified VWF (Wilfactin) 9 hours before procedure. One hour after surgical incision, she was given another dose of 20 IU/kg−1. Postoperative monitoring was marked by excessive drainage loss, which led to administration of 40 IU/kg−1. Mediastinal drains were removed on day 4, 1 hour after patient received 20 IU/kg−1. (FVIII:C = coagulant factor VIII; VWF:Ag = von Willebrand factor antigen; VWF:RCo = von Willebrand factor ristocetin cofactor.) The Annals of Thoracic Surgery , e423-e425DOI: ( /j.athoracsur ) Copyright © 2016 The Society of Thoracic Surgeons Terms and Conditions
3
Fig 2 Peri- and postoperative therapy in case 2. von Willebrand factor (VWF) concentrates (80 IU/kg−1) associated with factor VIII (FVIII) (35 IU/kg−1) were administered 1 hour before sternotomy. During postoperative period, patient immediately received 30 IU/kg−1 of purified VWF and then at 24 hours and 1 week later. (FVIII:C = coagulant factor VIII; VWF:Ag = von Willebrand factor antigen; VWF:RCo = von Willebrand factor ristocetin cofactor.) The Annals of Thoracic Surgery , e423-e425DOI: ( /j.athoracsur ) Copyright © 2016 The Society of Thoracic Surgeons Terms and Conditions
Similar presentations
© 2025 SlidePlayer.com. Inc.
All rights reserved.